SCH-37370
Code | Size | Price |
---|
TAR-T19686-1mg | 1mg | £147.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-5mg | 5mg | £227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-1mL | 1 mL * 10 mM (in DMSO) | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-10mg | 10mg | £295.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-25mg | 25mg | £474.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-50mg | 50mg | £655.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19686-100mg | 100mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
SCH-37370 is an effective and orally active dual antagonist of platelet-activating factor and histamine. Sch 37370 blocks the binding of [3H]pyrilamine to histamine-H1 receptors in rat brain membranes. Sch 37370 selectively inhibits PAF-induced aggregation of human platelets (IC50 : 0.6 mM) and also competes with PAF binding to specific sites in membrane preparations from human lungs (IC50 : 1.2 mM).
CAS:
117796-52-8
Formula:
C21H21ClN2O
Molecular Weight:
352.86
Purity:
0.9992
SMILES:
CC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12
Target:
Platelet aggregation
References
1. Kaminski JJ, Carruthers NI, Wong SC, Chan TM, Billah MM, Tozzi S, McPhail AT. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23. PubMed PMID: 10465415.
2. Centemeri C, Colli S, Tosarello D, Ciceri P, Nicosia S. Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages. Biochem Pharmacol. 1999 Feb 1;57(3):263-71. PubMed PMID: 9890553.
3. Negro Alvarez JM, Miralles L?pez JC, Ortiz Mart?nez JL, Abell?n Alem?n A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010.
4. Balsa D, Merlos M, Giral M, Ferrando R, Garc?a-Rafanell J, Forn J. Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard method. J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62. PubMed PMID: 8872920.